A new civil society group formed on February 21, 2024, aiming to advance precision medicine, particularly for women with triple-negative breast cancer who do not respond to chemotherapy. The organization’s founding reflects a growing focus on personalized treatment approaches in oncology, driven by the limitations of traditional therapies for aggressive cancer subtypes.
Triple-negative breast cancer (TNBC) is an aggressive form of the disease that lacks the estrogen, progesterone, and HER2 receptors found in other breast cancers. So that standard hormone therapies and HER2-targeted drugs are ineffective, leaving chemotherapy as the primary systemic treatment option. Although, TNBC often returns, and initial responses to chemotherapy can be limited. The new group intends to address this challenge by advocating for and supporting research into more tailored therapies.
Understanding the Challenges of Triple-Negative Breast Cancer
The “triple-negative” designation signifies the absence of three key receptors – estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). As explained by resources from the American Cancer Society, this lack of receptors means that treatments targeting these proteins are not useful for TNBC patients. Learn more about TNBC treatment options.
While TNBC initially responds well to chemotherapy in many cases, it has a higher risk of recurrence compared to other breast cancer types. This underscores the need for innovative treatment strategies that go beyond conventional chemotherapy. The newly formed civil society group seeks to accelerate the development and implementation of these strategies.
Advances in Treatment: Targeted Therapies and Immunotherapy
Recent advancements offer hope for improved outcomes in TNBC. According to Facing Our Risk, research presented at the San Antonio Breast Cancer Symposium in December 2023 highlighted the progress in targeted therapies and immunotherapies for both early and advanced stages of TNBC. Read about the latest advancements in TNBC treatment.
One promising development involves antibody-drug conjugates (ADCs), which combine chemotherapy drugs with antibodies that target cancer cells. These ADCs deliver chemotherapy directly to the tumor, potentially reducing side effects and improving efficacy. For patients with a BRCA1 or BRCA2 gene mutation, and specific tumor characteristics (tumor size between 2-5cm or cancer in 1-3 axillary lymph nodes), the targeted drug olaparib (Lynparza) may be administered after chemotherapy to help extend life expectancy.
The Role of Precision Medicine
The focus on precision medicine is central to the group’s mission. Precision medicine involves tailoring treatment to the individual characteristics of each patient’s cancer, including its genetic makeup and other molecular features. This approach aims to identify the most effective therapies for each patient, minimizing unnecessary side effects and maximizing the chances of success.
The Group’s Formation and Goals
The formation of this civil society group on February 21, 2024, signifies a collective effort to address the unmet needs of TNBC patients. The group’s goals include:
- Advocating for increased research funding for TNBC.
- Raising awareness about the challenges of TNBC and the importance of precision medicine.
- Supporting patients and families affected by TNBC.
- Facilitating collaboration between researchers, clinicians, and patient advocates.
The group’s establishment comes at a time when there is growing recognition of the need for more personalized approaches to cancer treatment. While chemotherapy remains a cornerstone of TNBC therapy, the emergence of targeted therapies and immunotherapies offers new hope for improving outcomes.
The group’s work will likely focus on ensuring that patients have access to the latest advancements in TNBC treatment, including genetic testing to identify those who may benefit from targeted therapies like olaparib. They will also likely advocate for broader access to clinical trials evaluating new treatment strategies.
treatment options for cancer are complex, and individualized. Patients should always discuss their treatment options with their healthcare provider to determine the best course of action for their specific situation.
Disclaimer: This article provides general information about triple-negative breast cancer and emerging treatment options. It is not intended to be a substitute for professional medical advice. Always consult with a qualified healthcare provider for diagnosis and treatment of any medical condition.
The next step for the newly formed group is to establish its organizational structure and begin outreach to stakeholders in the medical and patient advocacy communities. Further updates on their activities and initiatives will be available through their official channels. Share this article to help raise awareness about the challenges of triple-negative breast cancer and the importance of precision medicine.
